Elritercept

Unknown / undisclosed

Also known as TAK-226

Phase 3underway

Evidence outlook · registrational

Myelodysplastic Syndromes: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-09-15.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Myelodysplastic Syndromes
NCT07422480 · Takeda
2026-05-21 – 2033-10-01 · Myelodysplastic Syndrome, Anemia
What this study did
Other / comorbidity
NCT07623161 · Takeda
2026-09-10 – 2034-03-30 · Myelofibrosis, Anemia
What this study did
Phase 2 (3)
Myelodysplastic Syndromes
NCT07319845 · Takeda
2026-04-22 – 2033-01-10 · Myelodysplastic Syndromes
What this study did
NCT04419649 · Takeda
2020-08-19 – 2031-10-30 · Myelodysplastic Syndromes, Cytopenia
What this study did
Other / comorbidity
NCT05037760 · Takeda
2021-12-16 – 2030-02-28 · Myelofibrosis
What this study did

Competitive landscape

This drug's own stage for Myelodysplastic Syndromes: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Elritercept: this drugPhase 3UndisclosedActivin A/Bnot yet gradedNo reviewed efficacy summary in this indication
AzacitidineApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Imetelstat (Rytelo)ApprovedRNA / oligonucleotideTelomeraseReliable signalNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
AND017Phase 2Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
MomelotinibPhase 2Small moleculeJAK1 / JAK2 / ACVR1not yet gradedNo reviewed efficacy summary in this indication
R289Phase 1/2Small moleculeIRAK1/IRAK4not yet gradedNo reviewed efficacy summary in this indication
PF-08046040
—(overall)
UndisclosedCD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70not yet gradedNo reviewed efficacy summary in this indication
REGN17235
—(overall)
Multispecific antibodySLC3A2 x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Elritercept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
February 2028 (1)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2028-02-28 · NCT05037760 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Myelodysplastic SyndromesRecruiting
Est. primary completion 2028-06-26 · NCT07319845 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Myelodysplastic SyndromesRecruiting
Est. primary completion 2028-09-15 · NCT06499285 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 3Myelodysplastic SyndromesRecruiting
Est. primary completion 2029-04-30 · NCT07422480 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Myelodysplastic SyndromesRecruiting
Est. primary completion 2029-10-30 · NCT04419649 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Myelofibrosis, AnemiaRecruiting
Est. primary completion 2029-12-07 · NCT07623161 · CT.gov ↗
What to watch

See the full readout calendar ↗